Top 50 Clinical Trial Platform - Late Stage

Medable provides a digital platform for decentralized clinical trials that utilizes patient-generated data to enhance participant recruitment and streamline data collection. By integrating tools for remote scheduling, consent management, and real-time reporting, the platform improves the efficiency and quality of clinical research across over 60 countries.

Paradigm is developing a platform that integrates clinical trial management systems to enhance trial efficiency and reduce participation barriers for both patients and healthcare providers. By creating a unified infrastructure, Paradigm aims to provide equitable access to clinical trials, accelerating the delivery of potentially life-saving therapies.

ObvioHealth offers the ObvioGo® 2.0 platform, which utilizes digital tools for real-time data capture and participant engagement in clinical trials. This technology addresses inefficiencies in traditional trial management by providing customizable study designs and enhancing data accuracy, resulting in faster recruitment and improved compliance.

Science 37 operates an FDA‑inspected direct‑to‑patient clinical trial site that enables sponsors to conduct all study visits, assessments, and data capture in participants’ homes through a network of certified research nurses. The platform integrates with sponsor eCRF systems, provides real‑time source‑verified data, and expands recruitment nationwide to improve patient diversity and accelerate enrollment timelines. It supports therapeutic‑area agnostic protocols while maintaining GCP compliance and remote monitoring.

The startup has developed a biotech platform that integrates a network of clinical trial sites within existing medical practices, utilizing a mobile cohort of certified research coordinators and advanced software to enhance participant recruitment for research studies. This approach increases access to diverse human subjects for clinical trials, psychological research, and focus groups, addressing the challenge of limited participant availability in traditional drug development processes.

Teckro provides a data-driven platform that enhances site engagement in clinical trials through real-time analytics and targeted interventions. By quantifying site performance, Teckro improves recruitment rates and accelerates study timelines, delivering measurable outcomes for pharmaceutical and biotech sponsors.

H1 provides a health data platform that utilizes AI-enabled analytics to connect life sciences companies with healthcare professionals, enhancing clinical trial design and patient access. The platform addresses the challenge of identifying suitable investigators and optimizing diversity in clinical trials by delivering precise data insights and performance metrics.

ConcertAI is an AI-driven platform that utilizes real-world data and advanced analytics to enhance clinical trial design and execution in oncology. The company addresses the inefficiencies in cancer research by providing biopharma partners with actionable insights to accelerate drug development and improve patient outcomes.

Curebase provides decentralized clinical research software that enables efficient data collection through electronic patient-reported outcomes (ePRO) and electronic consent (eConsent) systems. The platform enhances participant engagement and accelerates study launches while ensuring high-quality data capture across diverse clinical trials.

Pi Health offers the Front-end Interoperable Capture System (FICS), a software platform that integrates disparate applications to streamline data collection for clinical trials. This technology enhances site-sponsor connectivity, reduces operational inefficiencies, and accelerates patient access to innovative medicines and cancer care.

Lindus Health operates as an anti-CRO, utilizing a proprietary software platform and access to 30 million Electronic Health Records to execute end-to-end clinical trials with fixed pricing and milestone-based payments. By streamlining study design, patient recruitment, and data management, Lindus delivers trials up to three times faster than traditional CROs, ensuring timely access to new treatments for patients.

Zephyr AI utilizes an AI-enabled platform that integrates diverse healthcare and biological data to identify optimal patient-drug matches and enhance clinical trial efficiency. This approach addresses the challenges of patient stratification and drug development costs, ultimately improving patient outcomes through personalized therapies.

The startup offers a remote patient research platform that integrates validated studies and connects with wearables and medical devices, facilitating seamless data transfer into existing systems. This technology enables biopharma and home health professionals to efficiently design and scale clinical research programs while ensuring compliance with data requirements.

The startup operates an integrated research organization that embeds clinical trials at the point of care, collaborating with healthcare providers to enhance patient participation and streamline data collection. This approach reduces the drug development timeline, improving access to clinical trials and outcomes for healthcare organizations.

Formation Bio offers an AI‑native platform that acquires clinical‑stage drug assets and accelerates their development through machine‑learning‑driven candidate scoring, automated trial design, and real‑time risk analytics. The cloud‑based solution integrates multi‑omics data, regulatory intelligence and secure collaboration tools, enabling pharmaceutical, biotech and academic partners to shorten milestones while generating revenue via licensing, milestone payments and royalties.

The startup is developing a Clinical Digital Twin Platform that creates virtual replicas of patients using real-time health data and advanced modeling techniques. This platform enables healthcare providers to personalize treatment plans and improve patient outcomes by simulating various clinical scenarios.

Unlearn.ai develops machine-learning models that create digital twins of clinical trial participants, enabling the use of synthetic patient data to enhance control groups. This technology accelerates clinical trials by allowing smaller study designs while maintaining statistical power, ultimately reducing the time and cost associated with bringing new therapies to market.

Lightship utilizes inclusive technology and flexible visit options to enhance patient participation in clinical trials, removing geographic barriers and providing personalized support throughout the research process. This approach addresses the limited access and choice often faced by patients and providers, accelerating the development of new therapies for diverse populations.

Truveta provides regulatory-grade electronic health record (EHR) data linked with social determinants of health, mortality, and claims data for over 120 million patients, enabling scientifically rigorous research. The platform addresses the need for high-quality, comprehensive data to support evidence generation in clinical trials, public health initiatives, and healthcare quality improvement.

Healthcare organizations often work with fragmented, incomplete, or outdated provider and patient data, which hampers efficient site selection for clinical trials, slows patient recruitment, and limits precise HCP engagement for medical affairs and commercial activities. Health plans also struggle with inaccurate provider directories, leading to network inefficiencies and suboptimal patient access. H1 delivers an integrated platform that combines software applications and curated data feeds to provide a single source of truth for clinicians, researchers, commercial teams, and payers.

N-Power Medicine embeds an always-on clinical research system into community oncology workflows via EHR integration, standardizing real-time data capture in the Kaleido Registry. This enables the creation of prospective external control cohorts for biopharma sponsors while accelerating patient enrollment and reducing documentation burden for physicians.

Tasso supplies FDA‑cleared, at‑home blood collection devices that obtain 200‑600 µL of capillary whole blood or dried‑blood spots via a painless, vacuum‑driven lancet, compatible with standard microtainer tubes or proprietary cartridges. The company also provides an end‑to‑end logistics and data platform (Tasso Connect) with prepaid shipping, remote proctoring, and a secure API/dashboard for real‑time sample tracking and integration with laboratory or EHR systems, supporting decentralized clinical trials and remote monitoring.

Mendel is an AI platform that combines large language models with a clinical hypergraph to enable physician-level cognitive reasoning for analyzing structured and unstructured clinical data. It enhances clinical data workflows by providing accurate cohort retrieval and chart review, ensuring outputs are explainable and grounded in a coherent patient journey.

Nucleai has developed an AI-powered platform that utilizes military-grade geospatial analysis to interpret complex cellular interactions in biopsy samples, generating spatial biomarkers for precision medicine. This technology enhances drug development by providing actionable insights that improve patient selection for clinical trials and optimize treatment strategies.

Owkin utilizes AI and multimodal patient data to identify biomarkers and match patient subpopulations with targeted drug candidates, enhancing the precision of drug discovery and development. This approach accelerates clinical trials and improves diagnostic accuracy, ultimately aiming to deliver the right treatment to each patient.

The startup develops clinically validated software applications that utilize artificial intelligence to analyze real-world data, enhancing patient outcomes and supporting the discovery of new medicines. By connecting patients, clinicians, and researchers, the platform generates extensive phenotypic databases that enable discovery research companies to maximize revenue in the healthcare sector.

Kyverna Therapeutics is developing CAR T-cell therapies to induce sustained treatment-free remission in patients with B cell-driven autoimmune diseases. Their clinical-stage platform includes autologous and allogeneic therapies currently undergoing trials for conditions such as lupus nephritis and multiple sclerosis.

This biotech startup utilizes a computational discovery engine to develop next-generation immunology nanobodies, enabling the creation of therapeutics with differentiated profiles at scale. By automating clinical trials, the company significantly reduces trial costs and enhances efficiency in drug development.

Exelixis runs an integrated oncology R&D platform that discovers and develops small‑molecule kinase inhibitors, bispecific antibodies and antibody‑drug conjugates for advanced solid tumors. The company advances candidates from target validation through global clinical trials and commercial launch, leveraging data‑driven selection and partnership models to expand its pipeline across indications such as renal cell carcinoma and colorectal cancer. Its products and investigational therapies are made available to oncologists and research teams via clinical‑trial enrollment and early‑access programs.

The startup specializes in matching cardiovascular disease drivers with treatment responders identified in clinical trials, utilizing advanced data analytics to enhance drug development processes. This approach ensures that patients gain access to targeted therapies that effectively address their specific heart health conditions.

Scholar Rock develops biologic and small‑molecule agents that modulate growth‑factor proteins before activation, aiming to intervene early in disease pathways. Its platform supports a pipeline across neuromuscular, cardiometabolic, immuno‑oncology, and fibrotic indications, with integrated preclinical, IND‑enabling, and clinical development and collaborations for expanded‑access studies.

BioAge provides a cloud‑based platform that generates multi‑omics biomarkers to quantify an individual’s biological age and predict health‑span trajectories. The service integrates genomics, transcriptomics, proteomics and metabolomics data with machine‑learning models, delivering calibrated age scores via a HIPAA‑compliant API and web dashboard for use by clinicians and pharmaceutical trial teams to personalize interventions and stratify study cohorts.

Elephas develops an imaging platform that utilizes multimodal microscopy and artificial intelligence to assess tumor microenvironments and predict patient responses to immunotherapy. This technology provides oncologists with critical data through a secure, cloud-based portal, enhancing clinical decision-making in cancer treatment.

AllStripes utilizes a Universal Patient Record powered by PicnicAI to streamline observational research and enhance patient care for rare diseases. The platform reduces research costs by 30-50% and accelerates patient enrollment, achieving a 98% retention rate year over year.

The company develops oral, enzyme‑targeted small‑molecule therapies that enhance glycolytic flux in red blood cells to increase ATP production and reduce hemolysis in rare hemolytic anemias such as pyruvate kinase deficiency, thalassemia, and sickle cell disease. Its platform combines structure‑based drug design, biomarker‑driven adaptive trials, and companion diagnostics to deliver disease‑modifying effects and support precision enrollment for hematologists and specialty clinics. Partnerships with pharmaceutical firms and academic centers accelerate development and broaden access to these metabolic treatments.

Develops a telemonitoring platform combining a clinical decision support system for oncologists and a mobile application for cancer patients, enabling remote tracking of treatment progress and adverse events. This solution improves patient quality of life, treatment adherence, and survival rates while streamlining care coordination in over 90 healthcare institutions.

Provides an AI-powered medical information platform that delivers evidence-based clinical insights and resources to healthcare professionals. It streamlines access to up-to-date medical knowledge, supporting informed decision-making across over 7,000 care centers in the United States. The platform is free and unlimited for healthcare providers, ensuring widespread availability and usage.

Immunai utilizes multi-omic single-cell analysis and machine learning to enhance drug development by optimizing clinical trials and evaluating preclinical assets. The company addresses the challenge of identifying effective treatment regimens and critical targets in human diseases, facilitating the advancement of immunomodulatory therapies.

Alto Neuroscience develops precision medicines for neuropsychiatric conditions using an AI-driven biomarker platform to predict clinical responses and identify patients most likely to benefit from their drug candidates. Their focus on major depressive disorder, bipolar depression, and schizophrenia aims to replace the trial-and-error approach in psychiatric treatment with targeted therapies based on deep neurobiological insights.

Alector uses a genetics‑first platform to identify protein pathways linked to neurodegeneration and develops CNS‑penetrant therapeutics—including monoclonal antibodies, engineered proteins, and gene‑delivery vectors—that clear toxic aggregates or modulate microglial activity. Its programs incorporate biomarker‑guided patient stratification and adaptive trial designs to accelerate development of disease‑modifying treatments for Alzheimer’s disease, frontotemporal dementia, and ALS.

Atropos Health develops a cloud-based Evidence Platform that converts electronic medical record data into high-quality Real-World Evidence, enabling healthcare organizations to make data-driven clinical decisions. This platform addresses the issue of insufficient evidence backing medical decisions, significantly reducing the time and resources required to generate actionable insights for patient care and research.

TigerConnect provides a cloud‑native clinical communication and collaboration platform that unifies secure messaging, alarm management, physician scheduling, and patient engagement into a single interface. The solution integrates with EHRs via FHIR and HL7 APIs, routes alerts in real time based on role and context, and offers analytics to optimize workflow efficiency for hospitals and other care settings.

VI is an Enterprise-AI platform that employs machine learning algorithms to analyze healthcare data, enhancing clinical decision-making through actionable insights. The platform aims to reduce diagnostic errors and optimize treatment plans, ultimately improving patient outcomes.

Virogin Biotech develops oncolytic HSV-1 viruses and mRNA-based therapeutics to generate robust anti-tumor immune responses against solid tumors. Their dual-platform approach enhances the efficacy of cancer immunotherapy, with candidates currently in clinical trials and preclinical stages.

Develops mRNA-based CAR-T cell therapies targeting autoimmune diseases, utilizing a proprietary platform to engineer safer and more potent therapeutic candidates. This approach addresses the limitations of traditional cell therapies by improving efficacy and reducing adverse effects, with ongoing clinical trials for conditions like myasthenia gravis.

Iterative Scopes provides real-time AI tools for colorectal cancer screening and surveillance, enhancing diagnostic accuracy for physicians. The platform aims to improve patient outcomes in gastrointestinal care by leveraging machine learning to optimize clinical research practices and treatment protocols.

BostonGene utilizes an AI-powered multi-omics platform to perform molecular and immune profiling, enabling precise therapy matching for patients with cancer and immune-related diseases. This approach identifies actionable mutations and biomarkers, generating personalized treatment roadmaps that enhance clinical decision-making and improve patient outcomes.

Acrivon Therapeutics utilizes its proprietary AP3 platform to match targeted cancer therapies with patients based on the biological drivers of their tumors, enhancing drug sensitivity detection beyond traditional genomic methods. This approach aims to improve therapeutic outcomes for patients with common and challenging cancers by ensuring that drug candidates are accurately aligned with those most likely to benefit from them.

1200 Pharma utilizes medicinal chemistry technologies to streamline pre-clinical drug discovery processes and reduce clinical trial timelines. By enhancing the efficiency of drug development, the company addresses the lengthy and costly nature of bringing new therapeutics to market.

BrightInsight provides a regulated digital health platform that enables biopharma and medtech companies to develop and manage Software as a Medical Device (SaMD) solutions, including companion apps and connected products. The platform enhances patient care by delivering measurable clinical and business outcomes, improving patient adoption and retention across various therapy areas.